Market news

Pre-commercial precision oncology firms often face steep financial trade-offs, where absent return on invested capital/ROIC and negative operating cash flows are the price of admission for long-term clinical innovation. IDEAYA Biosciences (NASDAQ:IDYA) operates from a position of relative balance sheet strength, backed by $1.24 billion in cash, cash equivalents, and marketable securities that extend its […]

Detailed price information for Monte Rosa Therapeutics Inc (GLUE-Q) from The Globe and Mail including charting and trades.

Detailed price information for Ideaya Biosciences Inc (IDYA-Q) from The Globe and Mail including charting and trades.

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced a successful FDA Type C meeting to determine the Phase 3 registrational trial design for IDE849, a potential best-in-class delta-like ligand 3 (DLL3)-targeting Topo-I-payload antibody drug conjugate (ADC), in extensive stage small cell lung cancer (ES-SCLC). IDEAYA is targeting to initiate the Phase 3 registrational study in ES-SCLC by year

IDEAYA Biosciences (IDYA) said Monday it held a US Food and Drug Administration meeting on the desig

IDEAYA Biosciences recently reported a second-quarter 2026 net loss of US$112.45 million, or US$1.22 per basic and diluted share, while also disclosing a wider six‑month loss versus the prior year. In parallel, IDEAYA advanced its precision oncology pipeline by initiating Part 2 monotherapy expansion for IDE892 and entering a clinical collaboration with Roche to explore combination regimens in MTAP‑deleted pancreatic cancer, an area with significant unmet medical need. With IDE892’s...

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on July 30, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 260,200 shares of the Company's common stock to fourteen newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award P

Briseno Andres Ruiz, Chief Accounting Officer, on July 07, 2026, sold 9,550 shares in Ideaya Bioscie